MAPT (Microtubule Associated Protein Tau)

LMOSGs play critical roles in UCEC heterogeneity, prognosis, and immune modulation. These genes represent promising biomarkers and potential targets for personalized therapeutic strategies.

Future research should focus on identifying optimal dosing strategies, understanding sex-specific responses, and elucidating the mechanisms underlying the synergistic effects of omega-3s with exercise. Overall, omega-3 PUFA supplementation represents a safe, accessible, and potentially effective nutritional strategy for attenuating muscle decline in aging and clinical populations, though its benefits appear most pronounced when combined with resistance exercise as part of a multimodal approach.

Patients with TN EZH2low tumours benefit more from ddAC, while EZH2high have a better outcome after TAC. High tubulin expression may predict docetaxel benefit if adjusted for sTILs. Further research with more patients is needed to find the best use of these biomarkers.

Single-cell RNA sequencing revealed MAPT upregulation in T cells, PLXDC1 enrichment in cancer-associated fibroblasts, and mild STC2 elevation in tumor-associated macrophages and endothelial cells. These findings identify key ECM-based biomarkers with potential for early detection, prognosis, and therapeutic targeting in HCC.

This review summarizes what is known about Big tau and what is missing toward a better understanding of how expansion via inclusion of exon 4a modifies tau's structural and functional properties. Our purpose is to inspire future studies that could lead to novel therapeutic strategies to mitigate tau aggregation in neurodegenerative diseases.

CTHRC1 overexpression in SH-SY5Y cells promoted tau degradation and modulated network partner expression. CTHRC1 represents a central hub in cognitive function networks, suggesting therapeutic potential for neurodegenerative disorders.

This study developed a prognostic model based on the potential target genes of DHM in HCC. This model effectively stratifies HCC patients, identifying a high-risk subgroup characterized by an immunosuppressive microenvironment. These findings provide a theoretical foundation for exploring DHM as a promising natural adjuvant for cancer immunotherapy.

This dual modulation-suppression of tau phosphorylation and facilitation of degradation-highlights abemaciclib as a promising repurposed therapeutic for AD. Our findings establish a novel pharmacological profile for abemaciclib beyond its canonical role in cell cycle control, offering immediate translational potential for tau-targeted AD therapy.

P=N/A, N=26, Completed, University of Pennsylvania | Active, not recruiting --> Completed

MBCE mitigates neurodegenerative pathology in AD and PD models by promoting AMPK-dependent autophagy and reducing toxic protein aggregation. These findings support the potential of MBCE as a functional food-based therapeutic strategy for neurodegenerative diseases. Please cite this article as: Chen ZX, Wang FP, Li YP, Wu MT, Chen MY, Huang FH, Wen YP, Wang XH, Yu L, Wu JM, Wu AG, Zhou XG. Neuroprotective activity of mung bean (Vigna radiata) coat extract via AMPK-dependent autophagy in Alzheimer's and Parkinson's models. J Integr Med. 2025; Epub ahead of print.

Very early onset behavioral variant frontotemporal dementia (bvFTD) is an uncommon clinical presentation of frontotemporal dementia (FTD). A review of the literature identified 18 patients with an onset age of 25 years or younger, with the youngest patient reported to be 14 years old. Due to its early onset and primarily neuropsychiatric symptoms, bvFTD is often misdiagnosed as a psychiatric condition. In these cases, the most commonly reported pathology is tau protein, while mutations are frequently found in the MAPT gene. This differs from typical FTD, where the most commonly reported pathology is TDP-43 protein. Although rare, it is important to consider bvFTD even in very young patients presenting with new, significant behavioral disturbances.

Biomarkers in FTLD are not only pivotal for diagnosis but also for tracking disease progression and monitoring response to emerging therapies. A comprehensive biomarker panel, incorporating markers of neurodegeneration, neuroinflammation, and specific pathology, may eventually enable personalized treatment approaches as well as evaluate the role of co-pathology.